Hepatocellular carcinoma
Conditions
Interventions
Intervention group (HCCScreen group):Alpha-fetoprotein (AFP)/B-ultrasonography + HCCScreen assay
Control group (AFP/B screening):Alpha-fetoprotein (AFP)/B-ultrasonography
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
Male
Age
35 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) The participants were already recruited in the community-based HBsAg-positive cohort which was established between Oct 1, 2017 and May 31, 2018; 2) The participants were from the following project sites: Qidong, Lingbi, Mengcheng, Dancheng, Shenqiu; 3) male aged 35-70 years; 4) willing to participate and competent to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Diagnosed as liver cancer before Jan 1, 2019; 2. Diagnosed as other cancer before Jan 1, 2019; 3. Be unable to participate in the screening process due to serious diseases; 4. Be allergic to the contrast agent of dynamic CT.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection rate of HCC;Proportion of HCC tumors of < 3 cm;Proportion of HCC tumor less than 5cm in diameter; | — |
Secondary
| Measure | Time frame |
|---|---|
| No-disease survial in 3 years;No-diasease survial in 5 years; | — |
Countries
China
Contacts
Public ContactChunfeng Qu
Cancer Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed